EMEA-002074-PIP01-16 - paediatric investigation plan
Ramucirumab
PIPHuman
Key facts
- Invented name
- Cyramza
- Cyramza
- Active Substance
- Ramucirumab
- Therapeutic area
- Oncology
- Decision number
- P/0282/2017
- PIP number
- EMEA-002074-PIP01-16
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma
- Treatment of intestinal malignant neoplasms
- Treatment of liver cancer
- Treatment of lung malignant neoplasms
- Treatment of urinary tract malignant neoplasm
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com
Tel. +44 (0)1276 483000- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date